CTLA4 and neoplasm: ICIs enhance antitumor immunity by blocking immune checkpoint molecules expressed on the surface of T lymphocytes and tumor cells, such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand (PD-L1) [22].